Xanthine oxidase (XO) is a source of reactive oxygen species production in the heart. However, pathophysiological role of XO has not been clarified in hypertensive heart disease. Thus, the present study examined the impacts of high salt (HS) intake and febuxostat (Fx), a XO inhibitor in Dahl salt-sensitive (Dahl-S) rats.
Heart failure (HF) is one of the common causes of cardiovascular mortality and global public health problem. 1, 2 The prevalence of HF with preserved ejection fraction (HFpEF) has been increasing among the elderly population, and it will be a common phenotype of HF. 3 Although HFpEF had lower total mortality than HF with reduced ejection fraction (HFrEF), absolute mortality was still high. 4 Evidence-based treatment for HFpEF has not been established yet, and new therapeutic strategies was required. 4, 5 Diastolic dysfunction which causes HFpEF has been defined with the increased left ventricular (LV) stiffness, and cardiac fibrosis is thought to be the main causing factor in the increased LV stiffness. 3, 6 In addition to cardiac fibrosis, cardiac hypertrophy is a histological feature of diastolic dysfunction. 6 A major cause of HF is hypertension. 1,2 Salt-sensitive hypertension is more closely associated with cardiovascular events than non-salt-sensitive hypertension. 7 A number of experimental and clinical studies indicate that oxidative stress is enhanced in HF. 8 Oxidative stress causes cardiac hypertrophy and collagen production in hypertensive heart disease. 6, 9 Reactive oxygen species (ROS) can be produced from several sources, including mitochondrial enzymes, nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase (XO), and uncoupled nitric oxide synthases. 8 XO is an enzyme responsible for the final two steps of purine catabolism: the oxidation of hypoxanthine to xanthine and to uric acid. 8 Several studies indicated an association between XO and HF. 10 The expression of XO protein increased in the heart of patients with idiopathic-dilated cardiomyopathy. 11 Uric acid was serected from the heart of HF patients, and its level could be a prognostic predictor. 12 Febuxostat (Fx) is a novel nonpurine selective inhibitor of XO. Fx has strong, long effects and does not generate or scavenge ROS by its chemical structure. 13 In contrast, allopurinol, a purine analogue XO inhibitor, produces ROS when metabolized to oxypurinol. 14 Because of its high clearance from liver, Fx is associated with fewer significant side effects and dose-adjustment is not necessary in patients with renal dysfunction. [15] [16] [17] Clinical studies reported that Fx ameliorated the cardiac function in HF patients with hyperuricemia 16 and that Fx decreased LV mass index in patients with hyperuricemia after cardiac surgery. 17 Animal studies reported beneficial effects of Fx in HF models including dogs with pace maker-induced tachycardia, rabbits with coronary artery ligation, Wistar rats administrated doxorubicin, and mice with transverse aortic constriction. [18] [19] [20] [21] [22] These reports indicated that Fx ameliorated cardiac function or prevented cardiac remodeling with reduction of oxidative stress. However, the effect of Fx has not been reported in the heart disease caused by salt-sensitive hypertension.
Dahl salt-sensitive (Dahl-S) rats increase blood pressure and cause cardiac or renal damage by high salt (HS) intake. 23, 24 They can be useful models of salt-sensitive hypertension, hypertensive heart disease, or HF. 9, 24 Several studies reported that oxidative stress increased in plasma and heart of Dahl-S rats. HS intake increased hydrogen peroxide in plasma. 25 The activity of xanthine oxidoreductase (XOR) and NADPH oxidase increased in the heart of Dahl-S rats with established HF, and XO inhibition with oxypurinol prevented the progression of cardiac remodeling. 9 However, the effect of Fx on heart disease has not been reported in Dahl-S rats. Thus, we hypothesized that Fx could suppress ROS generation and prevent pathological changes in the heart of Dahl-S rats even at an early stage of HF. To clarify the pathophysiological role of XO in the development of hypertensive heart disease, the present study examined effects of Fx on the HS intakeinduced cardiac hypertrophy and fibrosis in Dahl-S rats.
METHODS

Animals
Eight-week aged, male Dahl-S rats (Japan SLC Inc, Shizuoka, Japan) randomly assigned for 0.6% NaCl diet (normal salt: NS) group (n = 12), 8% NaCl diet (HS) group (n = 11), and HS + Fx (3mg/kg/day) group (n = 12). Febuxostat was kindly provided by Teijin Pharma Ltd. (Tokyo, Japan). Fx was administrated with drinking water. The concentration of Fx was determined according to our pilot study and previous report. 15 In pilot study, we administrated Fx at 1, 3, and 10mg/ kg/day to Dahl-S rats from 8 weeks, and there were no significant differences between 1 mg/kg/day group and HS group, and between 3 mg/kg/day group and 10 mg/kg/day group in LV weight at 16 weeks (data not shown). High-dose administration of XO inhibitor causes xanthine calculi and renal damage in rodents. 15 From these findings, we selected submaximal dose of Fx, namely, 3 mg/kg/day. In Dahl-S rats fed on HS diet from 8 weeks, normal LV geometry is decreased from 13 to 21 weeks of age, and LV posterior wall thickness (LVPWT) gradually increases and the ratio of peak early diastolic filling velocity (E velocity) and peak filling velocity at atrial contraction (A velocity) (E/A) gradually reduces until 21 weeks. 24 Furthermore, we found that there were no significant differences among NS, HS, and HS ± Fx groups in XO activity at 12 weeks (data not shown). To examine the effects of Fx on the early stage of HF, HS diet and Fx were fed until 16 weeks of age. Systolic blood pressure (SBP) was measured every 2 weeks with tail cuff method (MK-2000A; Muromachi Kikai, Tokyo, Japan). All of procedures were conducted according to the guidelines of the Animal Welfare Committee of Tohoku University School of Medicine.
Echocardiographic study
Transthoracic M-mode and Doppler echocardiographic studies were performed at 15 weeks of age, using an ultrasonographic system (Aplio, Toshiba, Tokyo, Japan) with a 10-MHz transducer. Rats were anesthetized with 2% isoflurane mixed with oxygen. LV end-diastolic and end-systolic diameters (LVDd and LVDs) and LVPWT were measured using M-mode tracing with short-axis views at the papillary muscle level. LV fractional shortening (LVFS) was calculated as follows: LVFS = [(LVDd − LVDs)/LVDd] × 100. Using pulse Doppler imaging, transitional inflow velocity was recorded from an apical 4-chanber view, in the half left-lateral position. E velocity and A velocity, and E/A were measured.
Plasma parameters
At 16 weeks of age, all rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and blood samples were collected by decapitation. Collected blood samples were centrifuged at 1,710 × g for 15 minutes, and the supernatants were collected and stored at −80 °C. Plasma uric acid, creatinine, and urea nitrogen were measured by a standard autoanalysis technique (Nagahama LSL, Inc., Shiga, Japan).
Preparation of left ventricular samples
The heart was quickly removed after decapitation, and the LV was isolated carefully. The weight of hearts and LV were measured, and the ratio of heart and LV weight to body weight were calculated, respectively. The papillary muscle portion was resected for histological examination. The rest of the LV was stored at −80 °C. Frozen LV tissues were homogenized in 50-mmol/l potassium phosphate buffer (pH 7.4) containing 1-mmol/l ethylenediaminetraacetic acid, 1-mmol/l dithiothreitol, and 0.1-mmol/l phenylmethylsulfonyl fluoride. The homogenates were centrifuged at 3,000 × g for 5 minutes, and the supernatants were collected. The protein concentration of homogenate samples was measured using ultraviolet spectrophotometer technique by NanoDrop instrument (NanoDrop 2000; Thermo Fisher Scientific, MA).
Histological examination
The papillary level of transverse LV was fixed in 10% neutral formalin and embedded in paraffin. For staining with hematoxylin-eosin and Masson's trichrome, paraffin section was cut out 3-µm thickness.
From the sections stained with hematoxylin-eosin, cross-sectional area (CSA) was measured in cardiomyocytes cut transversely at the nucleus level. We assessed at least 100 cells per LV and the average value was used for analysis. From the sections stained with Masson's trichrome, the interstitial fibrosis area was evaluated. We selected five fields at random and calculated the ratio of the area of Masson's trichrome-stained fibrosis to the total area of the myocardium. Both of evaluation were performed using ImageJ software (National Institutes of Health, MD).
Measurement of thiobarbituric acid-reactive substances
Lipid peroxidation in the samples was examined by measuring thiobarbituric acid-reactive substances (TBARS) formation. Plasma and LV tissue TBARS levels were measured using commercial assay kit (TBARS Assay Kit, Cayman Chemical Company, MI), as described previously. 26 
Measurement of XO activity and NADPH oxidase activity
Measurements of XO activity in LV homogenates were based on the pterin-based assay. 15 Oxidation of pterine by the XO enzyme generates a fluorescent product, isoxanthopterin. The homogenate sample of the LV (800-µg protein) was incubated with pterin (final concentration 50 μmol/l; Sigma-Aldrich, MO) to assay XO activity. After 45-minute incubation at 37 °C, fluorometric assays were performed to calculate the production of isoxanthopterin using a microplate reader (FlexStation3; Molecular Devices, CA; excitation 360 nm, emission 400 nm).
NADPH oxidase activity was measured using lucigeninenhanced chemiluminescence assay, as described previously. 26 Background value was subtracted and data were expressed count per minute (CPU)/mg of protein.
Western blot analysis
The LV homogenates (30-μg protein) were separated by electrophoresis on a 10% sodium dodecyl sulphate polyacrylamide gel. Proteins were transferred electrophoretically to nitrocellulose membranes and membranes were blocked by immersion into TBST-20 buffer (10-mmol/l Tris-HCl, 150-mmol/l NaCl, 0.08% Tween 20, and 5% nonfat dry milk). The membranes were then incubated at room temperature for 2 hours with primary antibodies raised against XO, extracellular signal-regulated kinase (ERK), phosphorylated ERK, transforming growth factor (TGF) -β1, angiotensin-converting enzyme (ACE), angiotensin II type1 (AT1) receptor (Santa Cruz Biotechnology, TX), type I collagen (Cosmo Bio, Tokyo, Japan), and β-actin (Sigma-Aldrich). Membranes were rinsed with TBST-20 and incubated at room temperature for 1 hour with a horseradish peroxidaseconjugated anti-goat, anti-rabbit, or anti-mouse IgG secondary antibody (Santa Cruz Biotechnology). After washing in TBST-20, immunoblots were developed using an enhanced chemiluminescent substrate (Super Signal; Thermo Fisher Scientific, MA).
The relative intensity of band was quantified using ImageJ. The intensity of band was normalized against it for β-actin, used as an internal standard, and was assigned a value of 1 in the NS group.
Statistical analysis
All data are presented as the mean ± SEM. Comparisons of three groups were done by one-way ANOVA followed by Turkey's test for multiple comparisons among the groups. A value of P < 0.05 was considered to be statically significant.
RESULTS
SBP, body weight, heart weight, LV weight, and plasma parameters Table 1 shows the SBP, body weight, heart weight, and LV weight at the end of experiment. After 8 weeks, HS intake significantly increased the SBP, and Fx significantly decreased the HS-increased SBP. HS intake significantly reduced body weight, whereas Fx significantly increased body weight. HS intake significantly increased the ratio of heart weight to body weight, and Fx significantly decreased it. Also, HS intake significantly increased the ratio of LV weight to body weight, and Fx significantly decreased them. HS intake significantly increased plasma uric acid and creatinine, and Fx significantly decreased them.
Echocardiography
HS intake significantly increased LVPWT (1.53 ± 0.06 vs. 2.27 ± 0.08 mm, P < 0.01), and Fx tend to decrease it (1.89 ± 0.14 mm, P < 0.1; Figure 1a and c). There were no differences in LVFS among the three groups (Figure 1d ). HS decreased E/A which indicates delayed relaxation (1.99 ± 0.07 vs. 1.14 ± 0.06, P < 0.01), and Fx increased it (1.64 ± 0.12, P < 0.01) (Figure 1b and e) .
Histology
Representative microphotograph showed that cardiomyocytes enlarged in the HS group compared with the NS group, and the sizes were reduced in the Fx group (Figure 2a) . Interstitial fibrosis area increased in the HS group compared with the NS group, and HS-induced fibrosis was attenuated in the Fx group (Figure 2b ). HS intake significantly increased CSA to 129% (P < 0.01), and Fx significantly suppressed the HS intake-increased CSA to 110% (P < 0.01) (Figure 2c ). HS intake significantly increased interstitial fibrosis area to 173% (P < 0.01), and Fx significantly suppressed the HS intake-increased area to 135% (P < 0.01) (Figure 2d ).
XO activity and NADPH oxidase activity
In the LV, HS intake significantly increased the expression of XO 4.9-fold (P < 0.01) (Figure 3a) , but Fx did not change the HS intake-increased expression (Figure 3a) . HS intake significantly increased the XO activity (0.07 ± 0.03 vs. 0.33 ± 0.05 mU/mg protein, P < 0.01), and Fx completely blocked it (P < 0.01) (Figure 3b) . HS intake also significantly increased the NADPH oxidase activity (852 ± 62 vs. 1266 ± 116 count per minute/mg protein, P < 0.01), and Fx significantly decreased it (670 ± 61 count per minute/mg protein, P < 0.01) (Figure 3c ).
Thiobarbituric acid-reactive substances
HS intake significantly increased TBARS in plasma (12.0 ± 0.65 vs. 23.8 ± 4.2 nmol/ml, P < 0.05), and Fx significantly decreased it (11.2 ± 0.80, P < 0.05) (Figure 3d ). HS intake also significantly increased TBARS in the LV (1.10 ± 0.07 vs. 2.08 ± 0.30 nmol/mg protein, P < 0.01), and Fx significantly decreased it (0.97 ± 0.34 nmol/mg protein, P < 0.01) (Figure 3e ). 
Protein expression and phosphorylation
HS intake significantly increased the expression of type I collagen and TGF-β1 by 56% and 91%, respectively, and Fx tended to decrease the type I collagen expression (P < 0.1) and significantly decreased the TGF-β1 expression (Figure 4a and b). HS intake also significantly increased the phosphorylation of ERK 2.6-fold, and Fx significantly decreased the phosphorylation (Figure 4c) .
HS intake significantly increased the expression of ACE 4.5-fold and AT1 receptor 2.2-fold, respectively, and Fx significantly decreased the expression (Figure 4d and e) .
DISCUSSION
XO is a source of ROS production in the heart. However, the pathophysiological role of XO has not been clarified at an early stage of hypertensive heart disease. To clarify the role of XO in the development of hypertensive heart disease, the present study examined the effects of Fx on the HS-induced cardiac hypertrophy and fibrosis in Dahl-S rats. The present study first demonstrated that Fx ameliorates the HS-induced cardiac hypertrophy and fibrosis. Interestingly, the present study also showed that Fx not only blocked XO but also inhibits the HS-activated NADPH oxidase and renin-angiotensin system (RAS) in the heart of Dahl-S rats.
The present study showed that Fx ameliorated the HS-induced cardiac remodeling and diastolic dysfunction in Dahl-S rats as well as HF models which were reported previously. [18] [19] [20] [21] [22] Because Fx also decreased systemic blood pressure in Dahl-S rats, it is not deniable that the antihypertensive effects of Fx might contribute to ameliorate cardiac remodeling and diastolic dysfunction. Thus, additional experiment was performed to examine the dependency of antihypertensive effects of Fx in cardiac remodeling and diastolic dysfunction. Hydralazine (10 mg/kg/day), which moderates blood pressure similarly to the Fx group, did not significantly ameliorate the HS-induced cardiac remodeling or diastolic dysfunction (data not shown). Allopurinol and oxypurinol were reported to ameliorate cardiac dysfunction and remodeling independently of blood pressure in heart disease models. 9, 27 In Dahl-S rats with established HF, oxypurinol ameliorated cardiac hypertrophy and fibrosis without changing blood pressure, whereas NADPH oxidase inhibitor apocynin did not ameliorate cardiac hypertrophy and fibrosis in spite of its antihypertensive effects. 9 It is possible that XO may play a critical role in progression of cardiac remodeling in Dahl-S rats with or without HF.
In agreement with previous studies in Dahl-S rats 9,28 and spontaneously hypertensive rats (SHR), 29 HS intake increased the XO activity, NADPH oxidase activity, expressions of ACE, AT1 receptor, and TGF-β1 and ERK activation in the heart of Dahl-S rats. TGF-β1 plays a role in cardiac hypertrophy and fibrosis, 30 and ERK is an important regulator of cardiac hypertrophy. 31, 32 TGF-β1 is activated by angiotensin II via AT1 receptor. 29, 30, 33 Allopurinol decreased XO activity and TGF-β1 mRNA expression in the heart of diabetic mice, 34 indicating that XO-produced ROS also activates TGF-β1. Isoproterenol increased the NADPH oxidaseproduced ROS and stimulated the ERK activity in the heart of mice, and antioxidant hydrogen-rich medium inhibited the ERK activation. 35 Oxypurinol inhibited the ERK activation in the LV of Dahl-S rats 9 and spontaneous hypertensive HF rats. 27 These findings suggest that NADPH oxidase and XO can stimulate the ERK activity in the heart.
Fx not only blocked XO activity but also inhibited the HS-increased NADPH oxidase activity and ACE and AT1 receptor expressions. There are a couple of studies regarding association between XO and angiotensin II. In note, allopurinol decreased angiotensin II and AT1 receptor expressions in the heart of Wistar rats fed a high-fat diet. 36 Allopurinol attenuated cardiac fibrosis and diastolic dysfunction in angiotensin II-infused mice. 37 Although precise mechanism is not clear, these findings suggest that XO inhibition could down-regulate RAS. In addition to XO inhibition, antioxidant hydrogen-rich saline reduced the ACE expression, angiotensin II, and NADPH oxidase activity in the heart of SHR, 38 suggesting that attenuated ROS could down-regulate RAS.
To the best of our knowledge, there are no report that XO affects NADPH oxidase directly. However, angiotensin II receptor blocker candesartan decreased both NADPH oxidase and XO activity in the heart of Dahl-S rats with HF. 9 NADPH oxidase inhibitor apocynin reduced XO expression in the angiotensin II-stimulated bovine aortic endothelial cells. 39 These findings suggest that angiotensin II stimulates XO via AT1 receptor and NADPH oxidase, and that there might be a crosstalk between XO and NADPH oxidase. Furthermore, oxypurinol did not decrease cardiac NADPH oxidase activity or blood pressure in Dahl-S rats with HF, 9 and hydralazine significantly decreased the HS intake-stimulated NADPH oxidase activity but not XO activity (data not shown), suggesting that the antihypertensive effects of Fx contributed to inhibit NADPH oxidase activity. Diastolic dysfunction is a bigger prognostic factor for mortality than the ejection fraction in HF patients. 3 Since the present study showed beneficial effects of Fx on cardiac remodeling and diastolic dysfunction with antihypertensive effects, XO inhibition from early phase of hypertension can prevent the development of HF and improve prognosis. XO inhibition may also can be one of the new therapeutic medications for HFpEF.
HS intake induces hypertension, LV hypertrophy, and fibrosis in Dahl-S rats, and Fx ameliorates the HS intakeinduced hypertension, LV hypertrophy, and fibrosis with decreasing the TGF-β1 expression and ERK phosphorylation. Fx also down-regulated the HS intake-stimulated NADPH oxidase and RAS. XO inhibition from early phase of hypertension may be an effective therapy to prevent the progression of hypertensive heart disease.
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